Synergys Receives Third NIH SBIR Grant from National Cancer Institute
October 10, 2022 14:08 ET
|
Synergys Biotherapeutics, Inc.
ALAMO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody fusion drugs, announced...